Cubist Pharmaceuticals, Inc. (NASDAQ:CBST)
| CAPS Rating |
|
|---|---|
| Open | $40.01 |
| Previous Close | $40.34 |
| Daily Range | $39.63 - $40.61 |
| 52-Week Range | $21.39 - $42.39 |
| Market Cap | $2.47B |
| P/E Ratio | 48.70 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 828,192 |
| Average Daily Volume | 0 |
CBST
VS S&P 500 (SPY)
How do you think CBST will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
CBST Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
CBST News and Commentary
- Alnylam Pharmaceuticals Shares Dropped: What You Need to Know – The Motley Fool
- Cubicin Drives Cubist Pharma - Analyst Blog – NASDAQ
- The Gory Details of Cubist Pharmaceuticals' Earnings Miss – The Motley Fool
- US STOCK FUTURES: HOT STOCKS TO WATCH – SmartMoney
- US STOCK FUTURES: HOT STOCKS TO WATCH – SmartMoney
- Earnings Preview: Cubist Pharma - Analyst Blog – NASDAQ
- Optimer Buoyant on Difficid Sales - Analyst Blog – NASDAQ
- Cubist's Preliminary Sales Impress - Analyst Blog – NASDAQ
- Cubist Pharma 4Q Revenue Tops Views; Cubicin Sales Up 25% – SmartMoney
- Magic Formula Investing 2011 Year in Review – Blog at The Motley Fool
- Trius Therapeutics Predicted to Rise on Rival to Pfizer Antibiotic – Minyanville
- The 2 Best-Performing Sectors Over the Last Decade – The Motley Fool
- Pipeline Progress at Cubist Pharma - Analyst Blog – NASDAQ
- Optimer's Dificlir Cleared in EU - Analyst Blog – NASDAQ
- Cubist Pharma Buys Adolor - Analyst Blog – NASDAQ
- Is Pharmacyclics the Perfect Stock? – The Motley Fool
- Still Bullish on Alnylam - Analyst Blog – NASDAQ
- Alnylam Completes Trial Enrollment - Analyst Blog – NASDAQ
- Alnylam Reveals ALNTTR01 Trial Data - Analyst Blog – NASDAQ
- Cubist Squares Well With These 2 Metrics – The Motley Fool
RSS Headlines
Fool UK
